The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer

Stephan B. Dreyer, MBChB, Arfon G. M. T. Powell, MSc, Stephen T. McSorley, MBChB, Ashita Waterston, PhD, James J. Going, PhD, Joanne Edwards, PhD, Donald C. McMillan, PhD, and Paul G. Horgan, PhD

1Institute of Cancer Science, University of Glasgow, Glasgow, UK; 2Institute of Cancer and Genetics, Cardiff University, Cardiff, UK; 3Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow, UK; 4Department of Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK; 5Section of Pathology, University of Glasgow, Glasgow, UK

ABSTRACT

Background. Not all patients respond equally to neoadjuvant chemoradiotherapy (nCRT), with subsequent effects on survival. The systemic inflammatory response has been shown to predict long-term outcomes in colorectal cancer. The current study examined the association between systemic inflammation and nCRT in patients with rectal cancer.

Methods. Between 1999 and 2010, patients who underwent nCRT were identified. Serum measurements of hemoglobin, C-reactive protein, albumin, modified Glasgow prognostic score (mGPS), and differential white cell counts were obtained before and after nCRT. The Rödel scoring system measured pathologic tumor regression, and magnetic resonance imaging and computed tomography determined radiologic staging.

Results. The study included 79 patients. Of these patients, 37% were radiologically downstaged, and 44% were categorized as showing a good pathologic response (Rödel scores 3 and 4). As a validated measure of the systemic inflammatory response, mGPS (P = 0.022) was associated with a poor pathologic response to nCRT. A radiologic response was associated with a good pathologic response to treatment (P = 0.003). A binary logistic regression model identified mGPS (odds ratio [OR] 0.27; 95% confidence interval [CI] 0.07–0.96; P = 0.043) and radiologic response (OR 0.43; 95% CI 0.18–0.99; P = 0.048) as strong independent predictors of a pathologic response to treatment.

Conclusion. The current study showed that a systemic inflammatory response before nCRT is associated with a poor pathologic response. Further study in a prospective controlled trial setting is warranted.

Colorectal cancer (CRC) is the third most common cancer and the second highest cause of cancer death in the United Kingdom. The 5-year survival rate for CRC still is less than 60% with surgery alone, offering the only chance of cure.

Rectal cancers comprise about one third of surgical resections for colorectal cancer. The widely adapted surgical technique of total mesorectal excision (TME), increased centralization, specialization of rectal surgery, and earlier disease detection have led to improved survival in the last 30 years. Preoperative neoadjuvant radiotherapy with or without chemotherapy currently is accepted as a standard of care for patients with margin-threatening rectal cancer. This increases disease-free survival (DFS) and sphincter preservation rates and improves circumferential resection margins and local recurrence rates.

Current management of CRC in the United Kingdom involves evaluating patients using magnetic resonance imaging (MRI) and computed tomography (CT) before treatment to identify those with margin-threatening disease (T3 or T4). These patients are offered neoadjuvant chemoradiotherapy (nCRT) before surgical resection.

Stephan B. Dreyer and Arfon G. M. T. Powell—contributed equally.

© The Author(s) 2016. This article is published with open access at Springerlink.com

First Received: 17 August 2016; Published Online: 21 November 2016

S. B. Dreyer, MBChB
e-mail: Stephan.Dreyer@glasgow.ac.uk
Not all patients respond to nCRT, and there is a need to identify biomarkers of response because treatment is associated with significant morbidity. Rödel et al. have shown that the presence of spontaneous apoptosis in the resected specimen is a good marker of tumor regression and improved prognosis.

The prognostic value of the systemic inflammatory response (SIR) has been widely studied in gastrointestinal cancers, particularly in the operative setting, using measurements of circulating markers including C-reactive protein (CRP), albumin, the modified Glasgow prognostic score (mGPS), the neutrophil lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and more recently, the neutrophil-platelet score (NPS) and the derived neutrophil-to-lymphocyte ratio (dNLR).

This study investigated the association between markers of the systemic inflammatory response and the pathologic response to nCRT in patients with rectal cancer.

METHODS

Patients who underwent nCRT and surgical resection for rectal adenocarcinoma between 1999 and 2010 were identified from a prospectively maintained colorectal cancer database. Patients with biopsy-confirmed adenocarcinoma of the rectum who received long-course nCRT and attempted curative resection were included in the study. Patients with margin-threatening disease and radiologic evidence of locally involved lymph nodes underwent nCRT as decided by the local colorectal cancer multidisciplinary teams. Patients were excluded from the study if they were considered unsuitable for long-course therapy, had undergone previous surgery for rectal cancer, or had documented chronic inflammatory conditions.

The patients were assessed and diagnosed according to standard national guidelines. Those with biopsy-confirmed rectal adenocarcinoma underwent staging CT and MRI to assess local extent of disease and evidence of metastases. These were repeated at the clinician’s request after nCRT for all the patients.

The nCRT regimen was at the discretion of the treating oncologists. Radiotherapy was delivered at a standard dose of 45 Gy in 25 fractions, with a range of 39.6–50 Gy. The concurrent chemotherapy regimens used included 5-fluorouracil (5-FU), capecitabine, or combinations of these with oxaliplatin and mitomycin.

CLINICOPATHOLOGIC CHARACTERISTICS

This study was approved by the West of Scotland Research Ethics Committee, Glasgow. Pathologic specimens were processed and reported by specialist gastrointestinal cancer pathologists, and final staging was reported as per the International Union Against Cancer (UICC) tumor-node-metastasis (TNM) staging system. This included a description of the lymph node ratio, the total lymph nodes retrieved, and tumor differentiation. Resection margin status was described as either free of tumor (R0), microscopically involved (R1), or macroscopically involved (R2).

Pretreatment blood test measurements were defined as the sample taken closest to the nCRT start date and included hemoglobin (Hb), neutrophil, lymphocyte and platelet counts, carcinoembryonic antigen (CEA), albumin, and CRP. Anemia was defined as levels lower than 13 g/dL (men) and lower than 11.5 g/dL (women). The CRP level was considered high if it exceeded 10 mg/L, and hypoalbuminemia was defined as a level lower than 35 g/L.

The mGPS was calculated as previously described. Briefly, patients with an elevated CRP were assigned an mGPS score of 1 or 2 depending on the presence or absence of hypoalbuminemia. The NLR and PLR were calculated as standard, with cutoffs of 5 or lower (NLR) and 300 or lower (PLR) considered normal. The NPS was calculated as recently described. Patients with a neutrophil count lower than 7.5 × 10⁹/L, and a platelet count lower than 400 × 10⁹/L scored 0. Those with either a neutrophil count higher than 7.5 × 10⁹/L or a platelet count higher than 400 × 10⁹/L scored 1, and those with both a neutrophil count higher than 7.5 × 10⁹/L and a platelet count higher than 400 × 10⁹/L scored 2. This measurement (the derived neutrophil-Lymphocyte ratio or dNLR) is calculated by the neutrophil count divided by the (white cell count minus the neutrophil count). The CEA was deemed normal at a value lower than 5 µg/L.

Assessment of Response to nCRT

Radiologic response to therapy was defined as tumor downstaging according to pre- and postneoadjuvant treatment imaging. The MRI and CT images were reported by dedicated gastrointestinal (GI) radiologists with a special interest in colorectal cancer.

Specimen sections were used to determine the pathologic response to therapy by quantifying the tumor regression grade (TRG) as validated previously. Tumor regression was quantified by the relative amount of fibrosis compared with residual viable tumor, ranging from no response to no evidence of viable tumor remaining. Each individual grade was defined as follows: grade 0 (no regression), grade 1 (minor regression: <25% of fibrosis in the tumor mass), grade 2 (moderate regression: 25–50% fibrosis within the tumor mass), grade 3 (good regression: dominant feature of fibrosis [≥50% fibrosis vs the tumor mass]), grade 4 (complete regression: no evidence of viable
tumor mass). Patients were dichotomized as having a good response (TRG 3 and 4) or a poor or no response (TRG 0, 1, and 2).

**Statistical Analysis**

Statistical evaluation was performed in SPSS (version 22.0; IBM SPSS Statistics, IBM Corp., Armonk, NY, USA). Grouping of the variables was performed using standard clinical thresholds. Comparisons between groups of patients were performed using contingency table analysis (Chi square) as appropriate, and Fisher’s exact test was used for those with n less than 5. Logistic regression was performed to determine univariate relationships between preoperative clinical predictors and response to nCRT. Multivariate logistic regression analysis, including all statistically significant covariates at a P value of 0.05 or lower, was performed by a stepwise backward procedure to derive a final model of the variables that had a statistically significant relationship between pathologic response and nCRT.

**RESULTS**

Clinicopathologic Characteristics

The study identified 176 patients who underwent nCRT and surgical resection for rectal cancer in the period 1999–2010. Patients not suitable for long-course chemoradiotherapy (n = 66), those who did not complete the course of chemoradiotherapy (n = 4), those who had no pretreatment blood results available (n = 10), and those who had no postoperative histopathology samples available (n = 17) were excluded from the study, leaving 79 patients included for the analysis.

The majority of the patients were male (n = 56, 70.1%), and the median age of the studied cohort was 65 years (range 39–84 years). At initial presentation and radiologic examination, the majority of the patients had T3 disease (n = 50, 63.3%), 74.7% (n = 59) were node-negative, and 7.6% (n = 6) had evidence of metastatic disease. During the neoadjuvant treatment course, 37 of the patients (46.8%) were radiologically downstaged, 38% had no stage change, and 15% (n = 12) progressed radiologically (Table 1). Using the Rödel classification, tumors were classified as 0 (0%), 1 (22%), 2 (34%), 3 (41%), or 4 (4%) and thus dichotomized as poor or having no response (n = 44, 55.7%) or as having a good response (n = 35, 44.3%). At the final pathologic staging, 3 patients (3.8%) had a complete pathologic response (pT0), 4 patients (5.1%) were stage pT1, 13 patients (16.5%) were stage pT2, 47 patients (59.5%) were stage pT3, and 12 patients (15.2%) were stage pT4 (Table 2).

The majority of the patients had a normal CRP (n = 43, 54.4%), a normal albumin (n = 64, 81%), an mGPS of 0 (n = 43, 54.4%), normal hemoglobin (n = 45, 57%), normal CEA (n = 32, 45%), an NLR of 5 or lower (n = 65, 82%), dNLR (n = 41, 52%), an NPS of 0 (n = 56, 71%), and a PLR of 300 or lower (n = 63, 80%) (Table 2).

Relationships Between Pretreatment Clinicopathologic Factors and Pathologic Response to Treatment

Pathologic response to CRT was significantly associated with pathologic T-stage (P < 0.001), TNM stage (P = 0.004), vascular invasion (P < 0.001), perineural invasion (P = 0.045), and radiologic response (P = 0.003) (Table 2). Nodal metastases (P = 0.189), CEA (P = 0.152), and type of chemotherapy (P = 0.875) were not associated with pathologic response to treatment (Table 2).

A good pathologic response to treatment was significantly associated with an mGPS of 0 (P = 0.022), a normal NLR (P = 0.052), and a PLR approaching significance (P = 0.071) (Table 2). There was no association between pathologic response to treatment and anemia (P = 0.321), dNLR (P = 0.705), or NPS (P = 0.928) (Table 2).

A logistic regression model using prognostic preoperative factors identified a high mGPS (odds ratio [OR] 0.27; 95% confidence interval [CI] 0.07–0.96; P = 0.043) and a poor radiologic response (OR 0.43; 95% CI 0.18–0.99; P = 0.048) as strong independent predictors of pathologic response to treatment (Table 3). In the univariate analysis, NLR (OR 0.27; 95% CI 0.08–0.98; P = 0.046) was associated with a pathologic response, but not in the multivariate analysis (Table 3). As shown in Table 3, PLR (P = 0.057), dNLR (P = 0.332), and NPS (P = 0.533) were not associated with a pathologic response to treatment. The preoperative logistic regression model was further tested with patients who had nonmetastatic disease only (n = 75). The findings showed that mGPS (hazard ratio [HR] 0.25; 95% CI 0.07–0.96; P = 0.022) but not radiologic response (HR 0.48; 95% CI 0.20–1.13; P = 0.094) remained an independent predictor of response to nCRT.

We next created a logistic regression model to test the predictive value of mGPS in the context of prognostic postoperative variables including vascular invasion, perineural invasion, and TNM staging (Table 4). We found that mGPS (OR 0.16; 95% CI 0.04–0.73; P = 0.018) remained a strong independent predictor of pathologic response, together with vascular invasion (OR 0.28; 95% CI 0.09–0.84; P = 0.023). Radiologic response (OR 0.59; 95% CI 0.22–1.62; P = 0.305) was not found to be
TABLE 1 Clinicopathologic characteristics of patients undergoing neoadjuvant chemoradiotherapy (nCRT) and surgery for rectal cancer

| Factors                              | Patients (n = 79) |
|--------------------------------------|------------------|
|                                      | n (%)            |
| Sex                                  |                  |
| Female                               | 23 (29)          |
| Male                                 | 56 (71)          |
| Age (years)                          |                  |
| <65                                  | 36 (46)          |
| 65–74                                | 34 (43)          |
| >75                                  | 9 (11)           |
| T-stage                              |                  |
| 0 (complete pathologic response)     | 3 (4)            |
| 1                                    | 4 (5)            |
| 2                                    | 13 (16)          |
| 3                                    | 47 (60)          |
| 4                                    | 12 (15)          |
| N-stage                              |                  |
| 0                                    | 50 (63)          |
| 1                                    | 14 (18)          |
| 2                                    | 15 (19)          |
| M-stage                              |                  |
| 0                                    | 75 (95)          |
| 1                                    | 4 (5)            |
| TNM stage                            |                  |
| 0                                    | 3 (4)            |
| 1                                    | 13 (16)          |
| 2                                    | 33 (42)          |
| 3                                    | 26 (33)          |
| 4                                    | 4 (5)            |
| Differentiation                      |                  |
| Moderately/well                      | 68 (86)          |
| Poor                                 | 10 (13)          |
| Unknown                              | 1 (1)            |
| Vascular invasion                    |                  |
| No                                   | 48 (61)          |
| Yes                                  | 30 (38)          |
| Unknown                              | 1 (1)            |
| Perineural invasion                  |                  |
| No                                   | 67 (85)          |
| Yes                                  | 9 (11)           |
| Unknown                              | 3 (4)            |
| Resection margin                     |                  |
| Not involved                         | 65 (82)          |
| Involved                             | 14 (18)          |
| Neoadjuvant chemotherapy regimen     |                  |
| Capecitabine                         | 27 (34)          |
| 5-FU                                 | 44 (56)          |
| Other                                | 8 (10)           |
| Surgical procedure                   |                  |

TABLE 1 continued

| Factors                              | Patients (n = 79) |
|--------------------------------------|------------------|
|                                      | n (%)            |
| Anterior resection                   | 38 (48)          |
| Abdominoperineal resection           | 30 (38)          |
| Hartmann’s resection                 | 2 (3)            |
| Unknown                              | 9 (11)           |
| Radiologic response                  |                  |
| Good response                        | 37 (47)          |
| No response                          | 30 (38)          |
| Disease progression                  | 12 (15)          |
| Pathologic response                  |                  |
| No response                          | 44 (56)          |
| Good response                        | 35 (44)          |

TNM tumor-node-metastasis, 5-FU 5-fluorouracil

significant in the model containing pre- and postoperative prognostic clinicopathologic variables.

DISCUSSION

The study showed an association between a systemic inflammatory response and a poor response to nCRT as determined by the Rödel tumor regression grade for patients undergoing surgery for rectal cancer. This is the first study to assess SIR comprehensively using a variety of prognostic markers of systemic inflammation and its association with response to neoadjuvant therapy in rectal cancer. The findings demonstrated that mGPS is independently associated with response to treatment and may offer further insight into the interaction between the host immune response and tumor regression.\textsuperscript{18,19} Our study further demonstrated that response to nCRT, assessed pathologically, is variable (good response of only 44%) and associated with adverse markers of long-term outcome including TNM stage, vascular invasion, and perineural invasion (Tables 1, 2).

Tumor regression grade offers a clinically useful parameter for determining variable rates of response to neoadjuvant therapy. Several scoring systems have been proposed based on the ratio of fibrosis and residual tumor cells, with fairly similar categorical determinants.\textsuperscript{11,20,21} These scoring systems predict improved disease-free and cancer-specific survival, but it remains to be determined which is best. The main advantage of this method is that it requires no additional laboratory testing or time and has good interobserver concordance. However, it has limitations. Semi-quantitative at best, it is based on selected areas of the tumor and may not fully account for intra-tumoral heterogeneity. Yet, allowing for its limitations, quantifying
| Clinicopathologic factors | No response patients (n = 44) | Good response patients (n = 35) | P value |
|--------------------------|------------------------------|-------------------------------|---------|
|                          | n (%)                        | n (%)                         |         |
| Sex                      |                              |                               |         |
| Female                   | 15 (34)                      | 8 (23)                        | 0.275   |
| Male                     | 29 (66)                      | 27 (77)                       |         |
| Age (years)              |                              |                               |         |
| <65                      | 16 (36)                      | 20 (57)                       | 0.127   |
| 65–74                    | 21 (48)                      | 13 (37)                       |         |
| >75                      | 7 (16)                       | 2 (6)                         |         |
| T-stage                  |                              |                               |         |
| 0 (complete pathologic response) | 0 (0)                     | 3 (9)                         | <0.001a |
| 1                        | 0 (0)                        | 4 (11)                        |         |
| 2                        | 3 (7)                        | 10 (29)                       |         |
| 3                        | 31 (70)                      | 16 (46)                       |         |
| 4                        | 10 (23)                      | 2 (6)                         |         |
| N-stage                  |                              |                               |         |
| 0                        | 24 (54)                      | 26 (74)                       | 0.189   |
| 1                        | 10 (23)                      | 4 (11)                        |         |
| 2                        | 10 (23)                      | 5 (14)                        |         |
| M-stage                  |                              |                               |         |
| 0                        | 41 (93)                      | 34 (97)                       | 0.399a  |
| 1                        | 3 (7)                        | 1 (3)                         |         |
| TNM stage                |                              |                               |         |
| 0                        | 0 (0)                        | 3 (0)                         | 0.004   |
| 1                        | 2 (4)                        | 11 (31)                       |         |
| 2                        | 22 (50)                      | 11 (31)                       |         |
| 3                        | 17 (39)                      | 9 (26)                        |         |
| 4                        | 3 (7)                        | 1 (3)                         |         |
| Differentiation          |                              |                               |         |
| Moderately/well          | 38 (86)                      | 30 (88)                       | 0.543a  |
| Poor                     | 6 (14)                       | 4 (12)                        |         |
| Vascular invasion        |                              |                               |         |
| No                       | 19 (43)                      | 29 (85)                       | <0.001  |
| Yes                      | 25 (57)                      | 5 (15)                        |         |
| Perineural invasion      |                              |                               |         |
| No                       | 36 (82)                      | 31 (97)                       | 0.045a  |
| Yes                      | 8 (18)                       | 1 (3)                         |         |
| Resection margin         |                              |                               |         |
| Not involved             | 34 (77)                      | 31 (89)                       | 0.156a  |
| Involved                 | 10 (23)                      | 4 (11)                        |         |
| Neoadjuvant chemotherapy regimen |                  |                               |         |
| Capecitabine             | 16 (36)                      | 11 (31)                       | 0.875   |
| 5-FU                     | 24 (55)                      | 20 (57)                       |         |
| Other                    | 4 (9)                        | 4 (11)                        |         |
| Surgical procedure       |                              |                               |         |
| Anterior resection       | 21 (48)                      | 17 (49)                       | 0.911   |
| Abdominoperineal resection | 16 (36)                      | 14 (40)                       |         |
| Hartmann’s resection     | 1 (2)                        | 1 (3)                         |         |
| Unknown                  | 6 (14)                       | 3 (9)                         |         |
the ratio of fibrosis to residual cancer tissue is the best method we currently have for predicting response to neoadjuvant therapy. However, this can only be used retrospectively after nCRT and thus cannot be used as a predictive biomarker before surgery.

Whereas findings have shown that pathologic response to nCRT, as measured by TRG, predicts recurrence and survival, the value of post-nCRT MRI remains controversial. Some studies have previously suggested poor correlation between posttreatment MRI appearances and clinical outcome. However, prospectively controlled studies have suggested that tumor regression can be accurately determined using post-nCRT MRI. A radiologic MRI assessment of tumor regression, as measured by the degree of fibrosis replacing pretreatment tumor, has been shown to correlate with both DFS survival and overall survival for patients with rectal cancer.

Recently, MRI volumetry has allowed more accurate assessment of tumor size than traditional uni-dimensional measurements. Reports show that MRI volumetry is an accurate predictor of pathologic response to treatment for patients who receive neoadjuvant therapy for rectal cancer. However, the reported studies contained small numbers and did not report correlation with overall survival and DFS. We observed strong associations between radiologic downstaging and pathologic response to nCRT, and thus radiologic response can be a useful adjunct in treatment decisions after nCRT.

In the absence of acute illness, what drives systemic inflammation is poorly understood, but chronic disease,

### TABLE 2 continued

| Clinicopathologic factors | No response patients ($n = 44$) | Good response patients ($n = 35$) | $P$ value |
|---------------------------|---------------------------------|---------------------------------|-----------|
| **Radiologic response**   |                                 |                                 |           |
| Disease progression       | 9 (21)                          | 3 (8)                           | 0.003     |
| No change                 | 22 (50)                         | 8 (23)                          |           |
| Good response             | 13 (29)                         | 24 (69)                         |           |
| mGPS                      |                                 |                                 |           |
| 0                         | 21 (55)                         | 22 (88)                         | 0.022     |
| 1                         | 9 (24)                          | 1 (4)                           |           |
| 2                         | 8 (21)                          | 2 (8)                           |           |
| **Hemoglobin**            |                                 |                                 |           |
| Normal ($>13$ g/dL [men]; $>11.5$ g/dL [women]) | 23 (53) | 22 (65) | 0.321 |
| Anemia ($<13$ g/dL [men]; $<11.5$ g/dL [women]) | 20 (47) | 12 (35) |   |
| **CEA**                   |                                 |                                 |           |
| Normal ($\leq 5$ µg/L)    | 14 (43)                         | 18 (62)                         | 0.152     |
| High ($>5$ µg/L)          | 18 (56)                         | 11 (38)                         |           |
| **NLR**                   |                                 |                                 |           |
| Normal ($\leq 5$)         | 33 (75)                         | 32 (91)                         | 0.052 a   |
| High ($>5$)               | 11 (25)                         | 3 (9)                           |           |
| **dNLR**                  |                                 |                                 |           |
| Normal ($<2$)             | 22 (50)                         | 19 (54)                         | 0.705     |
| High ($\geq 2$)           | 22 (50)                         | 16 (46)                         |           |
| **NPS**                   |                                 |                                 |           |
| 0                         | 31 (70)                         | 25 (71)                         | 0.928     |
| 1                         | 10 (23)                         | 7 (20)                          |           |
| 2                         | 3 (7)                           | 3 (9)                           |           |
| **PLR**                   |                                 |                                 |           |
| Normal ($\leq 300$)       | 32 (73)                         | 31 (89)                         | 0.071 a   |
| High ($>300$)             | 12 (27)                         | 4 (11)                          |           |

$^{a}$ Fisher’s exact test

*TNM* tumor-node-metastasis, *5-FU* 5-fluorouracil, *mGPS* modified Glasgow prognostic score, *CEA* carcinoembryonic antigen, *NLR* neutrophil-lymphocyte ratio, *dNLR* derived neutrophil-to-lymphocyte ratio, *PLR* platelet-to-lymphocyte ratio.
deprivation, and lifestyle changes have been implicated.\textsuperscript{28–30} It is likely, however, that in colorectal cancer, systemic inflammation is a response to the tumor and the tumor microenvironment itself. The pro-inflammatory cytokine interleukin-6 (IL-6), appears to play a key role in both local and systemic inflammation in colorectal cancer, with an association between IL-6 expression and more pronounced systemic inflammation (as measured by mGPS) in operable colorectal cancer.\textsuperscript{31,32} It has been proposed that elevated serum IL-6 is associated with tumor necrosis, angiogenesis, disease progression, and metastasis.\textsuperscript{31}

An elevated CRP has been associated with poor outcome after neoadjuvant therapy and surgery for rectal cancer.\textsuperscript{14,33} Kim et al.\textsuperscript{33} observed that CRP expression was significantly higher in nonresponders than in responders, consistent with our findings. We also demonstrated in the univariate analysis that NLR, but not PLR, was associated with response to therapy (Table 3). The prognostic value of NLR and PLR have been validated, and previous studies have demonstrated that both are associated with long-term outcomes for patients undergoing nCRT in rectal cancer.\textsuperscript{10,34} We did not find any correlation between dNLR and NPS with response to treatment, which recently has been claimed to be predictive of long-term outcomes in colorectal cancer.\textsuperscript{15,16}

This study demonstrated that a pretreatment mGPS score of 0 was independently prognostic of a pathologic response to chemoradiotherapy, even when analyzed in a model with prognostic postoperative variables such as TNM stage, vascular invasion, and perineural invasion (Tables 3, 4). Radiologic response assessed after treatment also was closely correlated with a good pathologic response and independently prognostic of such a response in the preoperative regression model (Table 3). This suggests that these preoperative measures can be used to assist

### TABLE 3
Comparison between preoperative clinical factors and good pathologic response to neoadjuvant chemoradiotherapy (nCRT)

|                      | Univariate analysis OR (95% CI)\textsuperscript{a} | P value | Multivariate analysis OR (95% CI)\textsuperscript{a} | P value |
|----------------------|-----------------------------------------------------|---------|-----------------------------------------------------|---------|
| mGPS (0 vs 1/2)      | 0.18 (0.05–0.60)                                    | 0.006   | 0.27 (0.07–0.96)                                    | 0.043   |
| NLR (normal/high)    | 0.27 (0.08–0.98)                                    | 0.046   | 0.72 (0.17–3.04)                                    | 0.658   |
| PLR (normal vs high) | 0.33 (0.11–1.03)                                    | 0.057   |                                                     |         |
| dNLR (normal vs high)| 0.73 (0.38–1.39)                                    | 0.332   |                                                     |         |
| NPS (normal vs high) | 0.77 (0.34–1.75)                                    | 0.533   |                                                     |         |
| Radiologic response  | 0.36 (0.18–0.71)                                    | 0.003   | 0.43 (0.18–0.99)                                    | 0.048   |

\textsuperscript{a} Odds ratios and 95% confidence intervals are generated from the logistic regression model

### TABLE 4
Comparison between pre- and postoperative clinicopathologic factors and a good pathologic response to neoadjuvant chemoradiotherapy (nCRT)

|                      | Univariate analysis OR (95% CI)\textsuperscript{a} | P value | Multivariate analysis OR (95% CI)\textsuperscript{a} | P value |
|----------------------|-----------------------------------------------------|---------|-----------------------------------------------------|---------|
| mGPS (0 vs 1/2)      | 0.18 (0.05–0.60)                                    | 0.006   | 0.16 (0.04–0.73)                                    | 0.018   |
| NLR (normal/high)    | 0.27 (0.08–0.98)                                    | 0.046   | 0.98 (0.22–4.39)                                    | 0.976   |
| PLR (normal vs high) | 0.33 (0.11–1.03)                                    | 0.057   |                                                     |         |
| dNLR (normal vs high)| 0.73 (0.38–1.39)                                    | 0.332   |                                                     |         |
| NPS (normal vs high) | 0.77 (0.34–1.75)                                    | 0.533   |                                                     |         |
| Radiologic response  | 0.36 (0.18–0.71)                                    | 0.003   | 0.59 (0.22–1.62)                                    | 0.305   |
| Vascular invasion    | 0.20 (0.08–0.52)                                    | 0.001   | 0.28 (0.09–0.84)                                    | 0.023   |
| Perineural invasion  | 0.13 (0.02–1.00)                                    | 0.050   | 0.62 (0.05–7.67)                                    | 0.713   |
| TNM stage (1/2 vs 3/4)| 0.50 (0.23–1.07)                                   | 0.074   |                                                     |         |
| Margin involvement   | 0.40 (0.13–1.28)                                    | 0.121   |                                                     |         |
| Peritoneal invasion  | 0.25 (0.05–1.18)                                    | 0.080   |                                                     |         |

\textsuperscript{a} Odds ratios and 95% confidence intervals are generated from the logistic regression model
in clinical decision making before surgeons proceed with surgery because pathologic response can be assessed only postoperatively. Interdependent postoperative prognostic pathologic variables such as TNM stage, vascular invasion, and perineural invasion are dependent on the pathologic response to nCRT. Thus, measures of SIR were tested in regression models using both pre- and postoperatively available variables to determine its prognostic utility in the pretreatment setting.

Several proposed biomarkers are reported to predict response to neoadjuvant therapy in rectal cancer, yet none have entered routine practice because of problems with methodology and validation. Serum CRP and albumin, however, are widely used as markers of systemic inflammation. The mGPS is validated as a marker of systemic inflammation and correlates with long-term survival after resection for colorectal carcinoma.1 This study was limited by a sample size slightly smaller than those in other published studies of this type.10,33 This reflects the difficulties of studying a small subtype of patients with colorectal cancer. However, our cohort had comprehensive assessment of the pretreatment systemic inflammatory response, which had not been performed in previous studies. Furthermore, only patients who completed long-course chemoradiotherapy were included in the study because findings have previously shown this to be superior to short-course radiotherapy alone.36

Our study did not aim to determine long-term survival and its association with SIR and response to neoadjuvant CRT in this patient cohort. Determinants of survival after resection for rectal cancer are multiple, including postoperative complications, adjuvant therapy, and surgical factors. Thus, our study focused on markers of response to treatment, which have previously been validated as predictors of long-term outcome.11,17

In conclusion, the current study demonstrated for the first time an association between the presence of a SIR and poor pathologic response to nCRT in patients with rectal cancer. We propose that our study results be validated in an independent cohort with strict follow-up data collection to assess this relationship with long-term survival. The role of anti-inflammatory or immune modulatory therapies in this setting requires further investigation to improve response to nCRT among patients with rectal cancer.

DISCLOSURE There are no conflicts of interest.

REFERENCES

1. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg. 2009;249:788–93.
2. Powell AG, Wallace R, McKee RF, Anderson J, Going JJ, Edwards J, et al. The relationship between tumour site, clinicopathological characteristics, and cancer-specific survival in patients undergoing surgery for colorectal cancer. Colorectal Dis. 2012;14:1493–9.
3. Fleming FJ, Pahlman L, Monson JR. Neoadjuvant therapy in rectal cancer. Dis Colon Rectum. 2011;54:901–12.
4. Verdeccia A, Guzzinati S, Francisci S, de Angelis R, Bray F, Allemani C, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer. 2009;45:1042–66.
5. Roh MS, Colangelo LH, O’Connell MJ, Youthers G, Deutsch M, Allegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABB R-03. J Clin Oncol. 2009;27:5124–30.
6. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.
7. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCICT CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811–20.
8. Quirke P. Training and quality assurance for rectal cancer: 20 years of data is enough. Lancet Oncol. 2003;4:695–702.
9. Group MS. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333:779.
10. Carruthers R, Tho LM, Brown J, Kakumanu S, McCartney E, McDonald E. Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Colorectal Dis. 2012;14:e701–7.
11. Rödel C, Martus P, Papadopoulos T, Fuzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–93.
12. Jamieson NB, Mohamed M, Oien KA, Foulis AK, Dickson EJ, Imrie CW, et al. The relationship between tumour inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2012;19:3581–90.
13. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149–63.
14. Toiyama Y, Inoue Y, Saigusa S, et al. C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery. Anticancer Res. 2013;33:5065–74.
15. Watt DG, Proctor MJ, Park JH, Horgan PG, McMillan DC. The neutrophil-platelet score (NPS) predicts survival in primary operable colorectal cancer and a variety of common cancers. PLoS ONE. 2015;10:e0142159.
16. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil-to-lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012;107:695–9.
17. Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014;32:1554–62.
18. Park JH, McMillan DC, Horgan PG, Roxburgh CS. The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer. *Cancer Treat Rev.* 2014;40:68–77.

19. Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. *Br J Cancer.* 2014;110:1409–12.

20. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. *Int J Colorectal Dis.* 1997;12:19–23.

21. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. *Cancer.* 1994;73:2680–6.

22. Hah JW, Kim HC, Lee SJ, Yun SH, Lee WY, Park YA, et al. Diagnostic accuracy and prognostic impact of restaging by magnetic resonance imaging after preoperative chemoradiotherapy in patients with rectal cancer. *Radiother Oncol.* 2014;113:24–8.

23. Seierstad T, Hole KH, Groholt KK, Dueland S, Ree AH, Flatmark K, et al. MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer. *Br J Radiol.* 2015;88:20150097.

24. Suppiah A, Hunter IA, Cowley J, Garimella V, Cast J, Hartley JE, et al. Magnetic resonance imaging accuracy in assessing tumour down-staging following chemoradiation in rectal cancer. *Colorectal Dis.* 2009;11:249–53.

25. Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. *J Clin Oncol.* 2011;29:3753–60.

26. Nougaret S, Fujii S, Addley HC, Bibeau F, Pandey H, Mikhael H, et al. Neoadjuvant chemotherapy evaluation by MRI volumetry in rectal cancer followed by chemoradiation and total mesorectal excision: Initial experience. *J Magn Reson Imaging.* 2013;38:726–32.

27. Aiba T, Uehara K, Nihashi T, Tsuzuki T, Yatsuya H, Yoshiioka Y, et al. MRI and FDG-PET for assessment of response to neoadjuvant chemotherapy in locally advanced rectal cancer. *Ann Surg Oncol.* 2014;21:1801–8.

28. Mathur N, Pedersen BK. Exercise as a mean to control low-grade systemic inflammation. *Mediators Inflamm.* 2008:109502, 2008.

29. Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. *Circulation.* 2003;108:414–9.

30. O’Reilly DS, Upton MN, Caslake MJ, Robertson M, Norrie J, McConnachie A, et al. Plasma C reactive protein concentration indicates a direct relation between systemic inflammation and social deprivation. *Heart.* 2006;92:533–5.

31. Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses, and outcome in patients with colorectal cancer? *Cancer Treat Rev.* 2013;39:89–96.

32. Waldner MJ, Foersch S, Neurath MF. Interleukin-6—a key regulator of colorectal cancer development. *Int J Biol Sci.* 2012;8:1248–53.

33. Kim IY, You SH, Kim YW. Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. *BMC Surg.* 2014;14:94.

34. Toiyama Y, Inoue Y, Kawamura M, Kawamoto A, Okugawa Y, Hiro J, et al. Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery. *Int Surg.* 2015;100:199–207.

35. Garcia-Florez LJ, Gomez-Alvarez G, Frunza AM, Barneo-Serra L, Martinez-Alonso C, Fresno-Forcelledo MF, et al. Predictive markers of response to neoadjuvant therapy in rectal cancer. *J Surg Res.* 2015;194:120–6.

36. Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. *Lancet Oncol.* 2014;15:184–90.